1. Home
  2. Analysis
  3. Methylprednisolone
  4. Neoplasm-recurrence

Methylprednisolone and Neoplasm recurrence - a phase IV clinical study of FDA data

Summary:

Neoplasm recurrence is reported as a side effect among people who take Methylprednisolone (methylprednisolone), especially for people who are female, 60+ old, have been taking the drug for 10+ years also take Tacrolimus, and have Acute leukaemia.

The phase IV clinical study analyzes which people have Neoplasm recurrence when taking Methylprednisolone. It is created by eHealthMe based on reports of 58,374 people who have side effects when taking Methylprednisolone from the FDA, and is updated regularly.

What is Methylprednisolone?

Methylprednisolone has active ingredients of methylprednisolone. It is often used in inflammation. eHealthMe is studying from 59,645 Methylprednisolone users. Check the latest studies of Methylprednisolone.

What is Neoplasm recurrence?

Neoplasm recurrence (reoccurrence of tumour) is found to be associated with 357 drugs and 495 conditions by eHealthMe. Check the latest studies of Neoplasm recurrence.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

58,374 people reported to have side effects when taking Methylprednisolone.
Among them, 32 people (0.05%) have Neoplasm recurrence.

Could Methylprednisolone cause Neoplasm recurrence?

Among these 32 people:

How long have people been on Methylprednisolone when they have Neoplasm recurrence? *

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 22.22 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 11.11 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 66.67 %

What is the gender of people who have Neoplasm recurrence when taking Methylprednisolone? *

  • female: 65.52 %
  • male: 34.48 %

What is the age of people who have Neoplasm recurrence when taking Methylprednisolone? *

  • 0-1: 0.0 %
  • 2-9: 6.9 %
  • 10-19: 3.45 %
  • 20-29: 0.0 %
  • 30-39: 31.03 %
  • 40-49: 10.34 %
  • 50-59: 3.45 %
  • 60+: 44.83 %

What are other drugs people take besides Methylprednisolone? *

  1. Tacrolimus: 14 people, 43.75%
  2. Mycophenolate Mofetil: 12 people, 37.50%
  3. Methotrexate: 8 people, 25.00%
  4. Cyclophosphamide: 7 people, 21.88%
  5. Cytarabine: 7 people, 21.88%
  6. Mesna: 5 people, 15.62%
  7. Cyclosporine: 5 people, 15.62%
  8. Cellcept: 4 people, 12.50%
  9. Vfend: 2 people, 6.25%
  10. Erythrocin: 2 people, 6.25%

What are other side effects people have besides Neoplasm recurrence? *

  1. Metastases To Lymph Nodes (cancer spreads to lymph node): 10 people, 31.25%
  2. Metastases To Pleura (cancer spreads to pleura): 10 people, 31.25%
  3. Metastases To Spine (cancer spreads to spine): 10 people, 31.25%
  4. Metastases To Bone (cancer spreads to bone): 10 people, 31.25%
  5. Metastases To Lung (cancer spreads to lung): 10 people, 31.25%
  6. Squamous Cell Carcinoma Of Skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin): 9 people, 28.12%
  7. Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 15.62%
  8. Febrile Neutropenia (fever with reduced white blood cells): 5 people, 15.62%
  9. Mucosal Inflammation (infection of mucous membrane): 5 people, 15.62%
  10. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 4 people, 12.50%

What are the existing conditions these people have? *

  1. Immunodeficiency Disorders: 5 people, 15.62%
  2. Acute Leukaemia (blood cancer): 5 people, 15.62%
  3. Bronchopulmonary Aspergillosis (lung disorder caused by aspergillus fungi): 2 people, 6.25%
  4. Malignant Neoplasm Progression (cancer tumour came back): 1 person, 3.12%
  5. Chronic Graft Versus Host Disease (immune cells attack the host's body cells after transplant): 1 person, 3.12%
  6. Acute Lymphocytic Leukaemia Recurrent (cancer in which the bone marrow makes too many lymphocytes-recurrent): 1 person, 3.12%
  7. Acute Graft Versus Host Disease (acute complication following an allogeneic tissue/blood transplant): 1 person, 3.12%

* Approximation only. Some reports may have incomplete information.

Do you take Methylprednisolone and have Neoplasm recurrence?

- Check whether Neoplasm recurrence is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Methylprednisolone:

Neoplasm recurrence treatments and more:

How severe was Neoplasm recurrence and when was it recovered:

Expand to all the drugs that have ingredients of methylprednisolone:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methylprednisolone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Neoplasm recurrence:

Browse all the conditions that are associated with Neoplasm recurrence:

How the study uses the data?

The study uses data from the FDA. It is based on methylprednisolone (the active ingredients of Methylprednisolone) and Methylprednisolone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.